K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation
Category: 2021
Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
20210409 – TG6002 AACR EN
Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
20210407 document AG EN
Availability of Transgene’s 2020 Universal Registration Document
20210401 Transgene mise a disposition ddr 2020 EN
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Tengku Ibrahim Maulana, et al. Adv Drug Deliv Rev., March 30 2021 – Read the article Publication
Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
20210310 Transgene TG4001 randomized Phase II EN
Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
20210310 Transgene Results 2020 EN
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 – Transgene Scientific Conferences
Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
20210301 – Transgene BT-001 FPI – EN
Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication
